JohnSKauhMDFACP
Oncology • New Brunswick, NJGastrointestinal Cancer, Hematologic Oncology
Chief Medical Officier Tvardi Therapeutics
Dr. Kauh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany Street
New Brunswick, NJ 08901Phone+1 732-235-7066Fax+1 732-235-8234
Education & Training
MedStart Georgetown University HospitalFellowship, Medical Oncology, 2000 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1997 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997
Certifications & Licensure
NJ State Medical License 2015 - 2025
GA State Medical License 2003 - 2017
DC State Medical License 2000 - 2008
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma Start of enrollment: 2004 Sep 01
- Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer Start of enrollment: 2006 Jan 01
- Study of MLN4924 in Adult Patients With Nonhematologic Malignancies Start of enrollment: 2008 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors.Apostolia M Tsimberidou, David J Vining, Sukeshi P Arora, Sofia de Achaval, Jeffrey Larson
Clinical Cancer Research. 2025-03-17 - 9 citationsPaediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicin...Andrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, Quentin Campbell-Hewson, Elizabeth R Lawlor
European Journal of Cancer. 2022-09-01 - 28 citationsLY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 do...Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal, Omid Hamid, Samuel J. Klempner
Investigational New Drugs. 2021-02-23
Professional Memberships
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
